NK/T cell lymphoma Hong Kong Experience with L-Asparaginase containing regimens. Y.L. Kwong University Department of Medicine Queen Mary Hospital
|
|
|
- Victoria Cox
- 5 years ago
- Views:
Transcription
1 NK/T cell lymphoma Hong Kong Experience with L-Asparaginase containing regimens Y.L. Kwong University Department of Medicine Queen Mary Hospital
2 Management of NK cell malignancies Principles 1. Accurate staging is needed for NK/T-cell at all anatomical locations 2. Non-nasal NK/T-cell lymphomas may have occult nasal involvement, and hence are disseminated nasal lymphomas 3. NK/T-cell lymphomas of all stages require chemotherapy 4. Radiotherapy alone should not be used
3 Cutaneous NK cell lymphoma, nasal type
4 Cutaneous NK/T cell lymphoma, nasal type Disseminated NK cell lymphoma
5 Management of NK cell malignancies Principles 1. Accurate staging is needed for NK/T-cell at all anatomical locations 2. Non-nasal NK/T-cell lymphomas may have occult nasal involvement, and hence are disseminated nasal lymphomas 3. NK/T-cell lymphomas of all stages require chemotherapy 4. Radiotherapy alone should not be used
6 L-asparaginase containing regimens
7 L-asparaginase containing regimens
8 Rationale for the SMILE protocol SMILE 1. Non-MDR dependent drugs: dexamethasone, ifosfamide, methotrexate 2. L-asparaginase: effective as a single agent 3. Etoposide (MDR-dependent): effective for CAEBV and other EBV related lymphoproliferation
9 SMILE protocol for NK cell lymphomas (K. Oshimi) 2 g/m 2 Methotrexate Folinic acid Daily MTX level 1.5g/m 2 Ifosphamide mesna 40mg/d Dexamethasone 100mg/m 2 etoposide 6000u/m 2 /d L-asparaginase G-CSF Days
10 SMILE in 87 cases of NK/T-cell lymphomas Overall survival
11 SMILE in 87 cases of NK/T-cell lymphomas Overall survival: newly-diagnosed
12 SMILE in 87 cases of NK/T-cell lymphomas Overall survival: relapsed / refractory
13 SMILE in 87 cases of NK/T-cell lymphomas Similar OS for newly-diagnosed and relapsed / refractory cases Newly diagnosed Relapsed / refractory
14 SMILE in 87 cases of NK/T-cell lymphomas Overall survival: IPI for prognostication P=0.001 Low High Low-Inter High-Inter
15 Non MDR related chemotherapy Promace-CytaBOM (III) DHAP (I) SMILE (II)
16 Non MDR related chemotherapy Promace-CytaBOM (III) + RT SMILE (II)
17 Prognostication of NK/T-cell lymphoma treated by SMILE Current prognostic models rely on constitutional features of the patients and lymphoma load Hypothesis Sensitivity of lymphoma cells to chemotherapy is a more important indicator of outcome
18 Lymphoma sensitivity to treatment Initial tumor bulk
19 NK/T-cell lymphoma Monitoring of response to SMILE 1. EBV DNA 2. PET/CT scan
20 NK/T-cell lymphoma Monitoring of response to SMILE 1. EBV DNA 2. PET/CT scan
21 Prognostic factors for SMILE Prospective evaluation of 1. Presentation EBV DNA 2. Non-detectable EBV DNA after SMILE 3. Dynamic patterns A. persistent non-detectable B. detectable, but < presentation C. detectable, but > presentation
22 Presentation EBV DNA for SMILE treated NK/T-cell lymphoma
23 Presentation plasma EBV DNA 1. Correlated very well with conventional parameters of tumor load, including LDH, IPI, KIPI, and remission 2. Did not correlate with overall survival or disease free survival 3. Implications: EBV DNA reflects tumor load, but tumor load is not the only factor that impacts on survival
24 Dynamic changes of EBV DNA 1. Reduction of EBV DNA after SMILE 2. Levels of EBV DNA during SMILE therapy A. non-detectable B. detectable, but < presentation C. detectable, but > presentation Dynamic changes reflect tumor sensitivity to SMILE therapy
25 Dynamic changes of EBV DNA 1. Reduction of EBV DNA after SMILE 2. Levels of EBV DNA during SMILE therapy A. non-detectable B. detectable, but < presentation C. detectable, but > presentation Dynamic changes reflect tumor sensitivity to SMILE therapy
26 Impact of negative EBV DNA after SMILE (I) on OS
27 Dynamic changes of EBV DNA 1. Reduction of EBV DNA after SMILE 2. Levels of EBV DNA during SMILE therapy A. non-detectable B. detectable, but < presentation C. detectable, but > presentation Dynamic changes reflect tumor sensitivity to SMILE therapy
28 Impact of dynamic EBV DNA changes on DFS
29 Prognostic factors for SMILE treated NK/T-cell lymphoma
30 Conclusions 1. Presentation EBV DNA reflects tumor load, but does not impact on survivals 2. Negative EBV DNA after SMILE (I) reflects superior response to chemotherapy, and therefore impacts on OS 3. For patients already in CR, non-detectable EBV DNA means optimal suppression of tumor cells, and therefore impacts on DFS
31 NK/T-cell lymphoma Monitoring of response to SMILE 1. EBV DNA 2. PET/CT scan
32 Role of interim PET/CT scan in SMILE Design 1. Baseline PET/CT 2. Interim PET/CT after 2 3 cycles 3. End-treatment PET/CT Parameters SUVmax, DSUVmax, tumor volume, 5-point Deauville score
33 Role of interim PET/CT in SMILE therapy Multivariate analysis OS Deauville 5-point score P < Multivariate analysis PFS Deauville 5-point score P < 0.001
34 Impact of mid-treatment PET/CT on OS
35 Impact of mid-treatment PET/CT on PFS
36 Impact of end-of-treatment PET/CT on OS
37 Impact of end-of-treatment PET/CT on PFS
38 Role of interim PET/CT in SMILE therapy Should aim at achieving a negative PET/CT scan after 2 3 cycles of SMILE Patients with a Deauville score of 4 5 at interim scan will not do well, and may require additional therapy to achieve durable remission
39 Which is more prognostic EBV DNA or PET/CT scan Interim assessments
40 Combined EBV DNA and PET/CT at end of treatment Prognostic impact
41 Combined EBV DNA and PET/CT at end of treatment Prognostic impact
42 Incorporation of presentation EBV DNA in prognostication Age Stage Nasal / non-nasal Nodal involvement EBV DNA (detectable / non-detectable)
43 Other L-asparaginase containing regimens
44 Acknowledgement NGTSG K. Oshimi R. Suzuki M. Yamaguchi ALSG W.S. Kim S.T. Lim
45 Acknowledgement
46 Acknowledgement
NK/T cell lymphoma Recent advances. Y.L Kwong University Department of Medicine Queen Mary Hospital
NK/T cell lymphoma Recent advances Y.L Kwong University Department of Medicine Queen Mary Hospital Natural killer cell lymphomas NK cell lymphomas are mainly extranodal lymphomas Clinical classification
Sandwich Chemotherapy (CT) with Radiotherapy (RT) Improves Outcomes in Patients with Stage I E. Extranodal Natural Killer (NK)/T-cell Lymphomas
DOI:http://dx.doi.org/10.7314/APJCP.2013.14.7.4061 Sandwich Chemotherapy with Radiotherapy Improves Outcomes with Stage I E /II (NK)/T-cell Lymphomas RESEARCH ARTICLE Sandwich Chemotherapy (CT) with Radiotherapy
East Midlands Cancer Network Guidelines for diagnosis and management of mature T cell and NK cell lymphomas (excluding cutaneous T cell lymphoma)
East Midlands Cancer Network Guidelines for diagnosis and management of mature T cell and NK cell lymphomas (excluding cutaneous T cell lymphoma) Written by: Dr Chris Fox with input from Dr Fiona Miall
Review Article Extranodal Natural-Killer/T-Cell Lymphoma, Nasal Type
Hindawi Publishing Corporation Advances in Hematology Volume 2010, Article ID 627401, 5 pages doi:10.1155/2010/627401 Review Article Extranodal Natural-Killer/T-Cell Lymphoma, Nasal Type Harinder Gill,
Original Study. Abstract
Original Study Management of Advanced and Relapsed/ Refractory Extranodal Natural Killer T-Cell Lymphoma: An Analysis of Stem Cell Transplantation and Chemotherapy Outcomes Jonathan E. Brammer, 1 Dai Chihara,
SMILE (Etoposide, Ifosfamide, Methotrexate and Dexamethasone)
SMILE (Etoposide, Ifosfamide, Methotrexate and Dexamethasone) INDICATION Natural Killer/T-cell lymphoma TREATMENT INTENT Curative SPECIAL PRECAUTIONS This protocol causes marked myelosuppression despite
Current treatment approaches for NK/T-cell lymphoma
Journal of clinical and experimental hematopathology Vol. 57 No.2, XXX-XXX, 2017 JC lin EH xp ematopathol Review Article Current treatment approaches for NK/T-cell lymphoma Motoko Yamaguchi, Kana Miyazaki
Efficacy of gemcitabine combined with oxaliplatin, L asparaginase and dexamethasone in patients with newly diagnosed extranodal NK/T cell lymphoma
1172 Efficacy of gemcitabine combined with oxaliplatin, L asparaginase and dexamethasone in patients with newly diagnosed extranodal NK/T cell lymphoma HONG QIANG GUO 1,2*, LEI LIU 1,2*, XIN FENG WANG
ISSN: (Print) (Online) Journal homepage:
Hematology ISSN: (Print) 1607-8454 (Online) Journal homepage: https://www.tandfonline.com/loi/yhem20 Effectiveness of pegaspargase, gemcitabine, and oxaliplatin (P-GEMOX) chemotherapy combined with radiotherapy
November Radiation Oncology Rotation, OHSU NK-T Cell Presentation. David Routman, MS4
November 2014 Radiation Oncology Rotation, OHSU NK-T Cell Presentation David Routman, MS4 Case Report Case - Presentation HPI: 44 y/o M referred to LAC+USC from OSH Originally presented with: Hearing loss
Int J Clin Exp Med 2018;11(4): /ISSN: /IJCEM
Int J Clin Exp Med 2018;11(4):3235-3244 www.ijcem.com /ISSN:1940-5901/IJCEM0064061 Original Article A retrospective clinical study: combined treatment of chemotherapy and radiotherapy results in optimal
ABSTRACT. Clinical Research Paper
/, 2016, Vol. 7, (No. 51), pp: 85584-85591 Phase II trial of concurrent chemoradiotherapy with L-asparaginase and MIDLE chemotherapy for newly diagnosed stage I/II extranodal NK/T-cell lymphoma, nasal
Peripheral T-cell lymphomas (PTCL) Specified and Unspecified. Eric Van Den Neste Cliniques universitaires Saint-Luc Bruxelles
Peripheral T-cell lymphomas (PTCL) Specified and Unspecified Eric Van Den Neste Cliniques universitaires Saint-Luc Bruxelles BHS seminar 12, 07 March 2015 Peripheral T-cell lymphomas (PTCL) Specified and
Treatment of localized extranodal NK/T cell lymphoma, nasal type: a systematic review
Kim et al. Journal of Hematology & Oncology (2018) 11:140 https://doi.org/10.1186/s13045-018-0687-0 REVIEW Treatment of localized extranodal NK/T cell lymphoma, nasal type: a systematic review Seok Jin
Aggressive NK-cell leukemia: Therapeutic potentials of L-asparaginase and allogeneic hematopoietic stem cell transplantation
Ishida F/ANKL07 1 Original article Aggressive NK-cell leukemia: Therapeutic potentials of L-asparaginase and allogeneic hematopoietic stem cell transplantation Fumihiro Ishida 1, Young Hyeh Ko 2, Won Seog
PREHYDRATION: 1000 ml NS with potassium chloride 20 meq and magnesium sulphate 2 g IV over 1 hour prior to CISplatin
BC Cancer Protocol Summary for Treatment of Newly Diagnosed Nasal, Extranodal Natural Killer (NK) or T-cell lymphoma, using Concurrent Radiation and weekly CISplatin followed by Etoposide, Ifosfamide,
Radiotherapy improves survival in early stage extranodal natural killer/t cell lymphoma patients receiving asparaginasebased
/, 2017, Vol. 8, (No. 7), pp: 11480-11488 Radiotherapy improves survival in early stage extranodal natural killer/t cell lymphoma patients receiving asparaginasebased chemotherapy Yi-Yang Li 1,2,3,*, Ling-Ling
Treatment outcomes of IMEP as a front-line chemotherapy for patients with peripheral T-cell lymphomas
BLOOD RESEARCH VOLUME 51 ㆍ NUMBER 3 September 2016 ORIGINAL ARTICLE Treatment outcomes of IMEP as a front-line chemotherapy for patients with peripheral T-cell lymphomas Ji Young Lee 1, Sang Min Lee 1,
Supplementary Appendix to manuscript submitted by Trappe, R.U. et al:
Supplementary Appendix to manuscript submitted by Trappe, R.U. et al: Response to rituximab induction is a predictive marker in B-cell post-transplant lymphoproliferative disorder and allows successful
Extranodal natural killer/t-cell lymphoma with long-term survival and repeated relapses: does it indicate the presence of indolent subtype?
VOLUME 47 ㆍ NUMBER 3 ㆍ September 2012 THE KOREAN JOURNAL OF HEMATOLOGY ORIGINAL ARTICLE Extranodal natural killer/t-cell lymphoma with long-term survival and repeated relapses: does it indicate the presence
Dr. A. Van Hoof Hematology A.Z. St.Jan, Brugge. ASH 2012 Atlanta
Dr. A. Van Hoof Hematology A.Z. St.Jan, Brugge ASH 2012 Atlanta DLBCL How to improve on R-CHOP What at relapse Mantle cell lymphoma Do we cure patients Treatment at relapse Follicular lymphoma Watch and
J Clin Oncol 29: by American Society of Clinical Oncology INTRODUCTION
VOLUME 29 NUMBER 33 NOVEMBER 2 211 JOURNAL OF CLINICAL ONCOLOGY O R I G I N A L R E P O R T Phase II Study of SMILE Chemotherapy for Newly Diagnosed Stage IV, Relapsed, or Refractory Extranodal Natural
Non-Hodgkin lymphoma
Non-Hodgkin lymphoma Non-Hodgkin s lymphoma Definition: - clonal tumours of mature and immature B cells, T cells or NK cells - highly heterogeneous, both histologically and clinically Non-Hodgkin lymphoma
LYMPHOMA IN OLDER PEOPLE. Ama Rohatiner, St. Bartholomew s Hospital, Londonj
LYMPHOMA IN OLDER PEOPLE Ama Rohatiner, St. Bartholomew s Hospital, Londonj LYMPHOMA IN OLDER PEOPLE PERSPECTIVES HALF OF ALL NEWLY-DIAGNOSED PTS. WITH LYMPHOMA ARE >60 MAY REQUIRE DIFFERENT MANAGEMENT
Lancashire and South Cumbria Haematology NSSG Guidelines for Follicular Lymphoma:
1 Lancashire and South Cumbria Haematology NSSG Guidelines for Follicular Lymphoma: 2018-19 1.1 Pretreatment evaluation The following tests should be performed: FBC, U&Es, creat, LFTs, calcium, LDH, Igs/serum
Changing the landscape of treatment in Peripheral T-cell Lymphoma
Changing the landscape of treatment in Peripheral T-cell Lymphoma Luis Fayad Associate Professor MD Anderson Cancer Center Department of Lymphoma and Myeloma 1 6 What is peripheral 2008 WHO CLASSIFICATION
Positron emission tomography/computed tomography in the diagnosis, staging, and prognostic evaluation of natural killer/t-cell lymphoma
Review Positron emission tomography/computed tomography in the diagnosis, staging, and prognostic evaluation of natural killer/t-cell lymphoma Journal of International Medical Research 2018, Vol. 46(12)
ABSTRACT INTRODUCTION
/, Vol. 6, No. 30 Post-treatment plasma EBV-DNA positivity predicts early relapse and poor prognosis for patients with extranodal NK/T cell lymphoma in the era of asparaginase Liang Wang 1,2,*, Hua Wang
How I Treat. How I treat NK/T-cell lymphomas. Introduction. Malignancies of putative NK-cell origin. Epidemiology of NK/T-cell lymphomas
How I Treat From www.bloodjournal.org by guest on November 23, 2018. For personal use only. How I treat NK/T-cell lymphomas Eric Tse and Yok-Lam Kwong Department of Medicine, Queen Mary Hospital, Hong
Kim et al. Journal of Hematology & Oncology 2013, 6:86
Kim et al. Journal of Hematology & Oncology 2013, 6:86 JOURNAL OF HEMATOLOGY & ONCOLOGY RESEARCH Open Access Extranodal natural killer/t-cell lymphoma involving the gastrointestinal tract: analysis of
FDG PET for therapy response assessment in lymphoma: Beyond Lugano Classification
FDG PET for therapy response assessment in lymphoma: Beyond Lugano Classification Yan Xuexian, MD, DABNM Department of Nuclear Medicine and PET, SGH National Cancer Center Singapore Duke-NUS Medical School
Update: Non-Hodgkin s Lymphoma
2008 Update: Non-Hodgkin s Lymphoma ICML 2008: Update on non-hodgkin s lymphoma Diffuse Large B-cell Lymphoma Improved outcome of elderly patients with poor-prognosis diffuse large B-cell lymphoma (DLBCL)
Traitement des lymphomes diffus à grandes cellules B
Traitement des lymphomes diffus à grandes cellules B Corinne HAIOUN Unité Hémopathies Lymphoïdes- CHU Henri Mondor Université Paris Est Créteil DES Hématologie Février 2012 On February 10th, the merging
Efficacy of a pegaspargase-based regimen in the treatment of newly-diagnosed extranodal natural killer/t-cell lymphoma
Neoplasma 61, 2, 2014 225 doi:10.4149/neo_2014_029 Efficacy of a pegaspargase-based regimen in the treatment of newly-diagnosed extranodal natural killer/t-cell lymphoma L. LI, C. ZHANG, L. ZHANG, X. LI,
PET-CT in Peripheral T-cell Lymphoma: To Be or Not To Be
PET-CT in Peripheral T-cell Lymphoma: To Be or Not To Be Bruce D. Cheson, M.D. Georgetown University Hospital Lombardi Comprehensive Cancer Center Washington, DC, USA So What is the Question(s)? What is
Recent diagnostic and therapeutic innovations of T-cell-lymphoma. Prof. Nossrat Firusian, Recklinghausen, Germany
Recent diagnostic and therapeutic innovations of T-cell-lymphoma Prof. Nossrat Firusian, Recklinghausen, Germany NODAL Angioimmunoblastic T-cell Lymphoma Peripheral T-cell-Lymphoma Anaplastic Large-cell-Lymphoma
Extranodal NK T-cell lymphoma, nasal type: New staging system and treatment strategies. Subtypes of NK T-Cell Lymphoma
Review Article Extranodal NK T-cell lymphoma, nasal type: New staging system and treatment strategies Tae Min Kim 1,2 and Dae Seog Heo 1,2,3 1 Department of Internal Medicine, Seoul National University
DERBY-BURTON LOCAL CANCER NETWORK FILENAME SMILE.DOC CONTROLLED DOC NO: HCCPG B57 CSIS Regimen Name: SMILE. SMILE chemotherapy
SMILE chemotherapy Available for Routine Use in Burton in-patient Derby in-patient Burton day-case Derby day-case Burton community Derby community Burton out-patient Derby out-patient Indication Extranodal
THE NEW ARMENIAN MEDICAL JOURNAL
Abstract THE NEW ARMENIAN MEDICAL JOURNAL Address for Correspondence: Vol.11 (2017), Nо 2, p. 10-15 HEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS IN A PATIENT WITH EXTRANODAL NATURAL KILLER LYMPHOMA, NASAL TYPE,
Who should get what for upfront therapy for MCL? Kami Maddocks, MD The James Cancer Hospital The Ohio State University
Who should get what for upfront therapy for MCL? Kami Maddocks, MD The James Cancer Hospital The Ohio State University Treatment Challenges Several effective options, improve response durations, none curable
Therapeutic Radiology and Oncology, 2018
Original Article Page 1 of 9 Preliminary study of integrating pretreatment and early followup FDG-PET in patients with localized nasal natural killer/t-cell lymphoma receiving concurrent chemoradiotherapy
LYSA PET adapted programs. O. Casasnovas Hematology department Hopital Le Bocage, CHU Dijon, France
LYSA PET adapted programs O. Casasnovas Hematology department Hopital Le Bocage, CHU Dijon, France 3 phase III trials DLBCL LNH 09-1B: aaipi = 0, 18 80y : ongoing GAINED: aaipi = 1-3, 18 60y : ongoing
ESHAP Salvage Therapy for Refractory and Relapsed Non-Hodgkin s Lymphoma: A Single Center Experience
The Korean Journal of Internal Medicine: 21:159-164, 2006 ESHAP Salvage Therapy for Refractory and Relapsed Non-Hodgkin s Lymphoma: A Single Center Experience Sang Hyoung Park, M.D., Shin Kim, R.N., Ok
Acute Lymphoblastic Leukemia (ALL) Ryan Mattison, MD University of Wisconsin March 2, 2010
Acute Lymphoblastic Leukemia (ALL) Ryan Mattison, MD University of Wisconsin March 2, 2010 ALL Epidemiology 20% of new acute leukemia cases in adults 5200 new cases in 2007 Most are de novo Therapy-related
Peripheral T-cell lymphoma. Matt Ahearne Clinical Lecturer, Leicester
Peripheral T-cell lymphoma Matt Ahearne Clinical Lecturer, Leicester PTCL Objectives To understand the natural history of PTCL To appreciate the importance of accurate diagnosis of PTCL including recent
ASCO abstract June 2007 :Othieno-Abinya NA, Abwao HO, Kiarie GW)
Inferior outcome of poor prognostic phenotype non- Hodgkin s lymphoma treatment among HIV positive patients compared with HIV negative counterparts in the HAART era. (ASCO abstract June 2007 :Othieno-Abinya
Sarajevo (Bosnia Hercegivina) Monday June :30-16:15. PET/CT in Lymphoma
Sarajevo (Bosnia Hercegivina) Monday June 16 2013 15:30-16:15 PET/CT in Lymphoma FDG-avidity Staging (nodal & extra nodal) Response evaluation Early assessment during treatment / interim (ipet) Remission
Outcomes of patients with peripheral T-cell lymphoma in first complete remission: data from three tertiary Asian cancer centers
Tang et al. (2017) 7:653 DOI 10.1038/s41408-017-0030-y CORRESPONDENCE Outcomes of patients with peripheral T-cell lymphoma in first complete remission: data from three tertiary Asian cancer centers Open
ABSTRACT INTRODUCTION. Jianzhong Cao 1,*, Shengmin Lan 1,*, Liuhai Shen 2, Hongwei Si 2, Ning Zhang 1, Hongwei Li 1, Ruyuan Guo 1
/, 2017, Vol. 8, (No. 12), pp: 20362-20370 A comparison of treatment modalities for nasal extranodal natural killer/t-cell lymphoma in early stages: The efficacy of CHOP regimen based concurrent chemoradiotherapy
What are the hurdles to using cell of origin in classification to treat DLBCL?
What are the hurdles to using cell of origin in classification to treat DLBCL? John P. Leonard, M.D. Richard T. Silver Distinguished Professor of Hematology and Medical Oncology Associate Dean for Clinical
PET-imaging: when can it be used to direct lymphoma treatment?
PET-imaging: when can it be used to direct lymphoma treatment? Luca Ceriani Nuclear Medicine and PET-CT centre Oncology Institute of Southern Switzerland Bellinzona Disclosure slide I declare no conflict
The serum CXCL13 level is associated with the Glasgow Prognostic Score in extranodal NK/T-cell lymphoma patients
Kim et al. Journal of Hematology & Oncology (2015) 8:49 DOI 10.1186/s13045-015-0142-4 JOURNAL OF HEMATOLOGY & ONCOLOGY RAPID COMMUNICATION Open Access The serum CXCL13 level is associated with the Glasgow
Strategies for the Treatment of Elderly DLBCL Patients, New Combination Therapy in NHL, and Maintenance Rituximab Therapy in FL
New Evidence reports on presentations given at ASH 2009 Strategies for the Treatment of Elderly DLBCL Patients, New Combination Therapy in NHL, and Maintenance Rituximab Therapy in FL From ASH 2009: Non-Hodgkin
PET-Guided Treatment Approach for Advanced Stage Classical Hodgkin Lymphoma. Ranjana H. Advani, MD
PET-Guided Treatment Approach for Advanced Stage Classical Hodgkin Lymphoma Ranjana H. Advani, MD Stanford Cancer Institute Management of Hodgkin Lymphoma Learning Objectives Review risk adapted strategies
AHSCT in Hodgkin lymphoma - indication and challenges. Bastian von Tresckow German Hodgkin Study Group Cologne University Hospital
AHSCT in Hodgkin lymphoma - indication and challenges Bastian von Tresckow German Hodgkin Study Group Cologne University Hospital AHSCT in Hodgkin Lymphoma The role of AHSCT in HL Mobilisation failure
Prognostic value of whole-body SUVmax of nodal and extra-nodal lesions detected by 18 F-FDG PET/CT in extra-nodal NK/T-cell lymphoma
/, 2017, Vol. 8, (No. 1), pp: 1737-1743 Prognostic value of whole-body SUVmax of nodal and extra-nodal lesions detected by 18 F-FDG PET/CT in extra-nodal NK/T-cell lymphoma Jin-Hua Liang 1,*, Chong-Yang
Relapsed/Refractory Hodgkin Lymphoma
Relapsed/Refractory Hodgkin Lymphoma Anas Younes, MD Chief, Lymphoma Service Memorial Sloan-Kettering Cancer Center New York, New York, United States Case Study 32-year-old woman was diagnosed with stage
Lugano classification: Role of PET-CT in lymphoma follow-up
CAR Educational Exhibit: ID 084 Lugano classification: Role of PET-CT in lymphoma follow-up Charles Nhan 4 Kevin Lian MD Charlotte J. Yong-Hing MD FRCPC Pete Tonseth 3 MD FRCPC Department of Diagnostic
ABSTRACT INTRODUCTION
/, Vol. 7, No. 20 Efficacy of combined gemcitabine, oxaliplatin and pegaspargase (P-gemox regimen) in patients with newly diagnosed advancedstage or relapsed/refractory extranodal NK/T-cell lymphoma Jing-hua
The treatment of DLBCL. Michele Ghielmini Medical Oncology Dept Oncology Institute of Southern Switzerland Bellinzona
The treatment of DLBCL Michele Ghielmini Medical Oncology Dept Oncology Institute of Southern Switzerland Bellinzona NHL frequency at the IOSI Mantle Cell Lymphoma 6.5 % Diffuse Large B-cell Lymphoma 37%
NCCN Non Hodgkin s Lymphomas Guidelines V Update Meeting 06/14/12 and 06/15/12
NCCN Non Hodgkin s Lymphomas Guidelines V.1.213 Update Meeting 6/14/12 and 6/15/12 Guidelines Page and Request Chronic Lymphocytic Leukemia/ Small Lymphocytic Lymphoma (CLL/SLL) Panel Discussion References
Linfoma de Hodgkin. Novos medicamentos. Otavio Baiocchi CRM-SP
Linfoma de Hodgkin Novos medicamentos Otavio Baiocchi CRM-SP 96.074 Hodgkin Lymphoma Unique B-cell lymphoma HRS malignant cells Scattered malignant Hodgkin-Reed-Sternberg (RS) cells in a background of
NICaN Testicular Germ Cell Tumours SACT protocols
Reference No: Title: Author(s) Ownership: Approval by: Systemic Anti-Cancer Therapy (SACT) Guidelines for Germ Cell Tumours Dr Audrey Fenton Consultant Medical Oncologist, Dr Vicky Coyle Consultant Medical
The DDGP (cisplatin, dexamethasone, gemcitabine, and pegaspargase) regimen for treatment of extranodal natural killer (NK)/T-cell lymphoma, nasal type
/, Vol. 7, No. 36 The DDGP (cisplatin, dexamethasone, gemcitabine, and pegaspargase) regimen for treatment of extranodal natural killer (NK)/T-cell lymphoma, nasal type Lei Zhang 1, Sucai Li 1, Sisi Jia
Diffuse Small Noncleaved-Cell, Non-Burkitt's Lymphoma in Adults: A High-Grade Lymphoma Responsive to ProMACE-Based Combination Chemotherapy
Diffuse Small Noncleaved-Cell, Non-Burkitt's Lymphoma in Adults: A High-Grade Lymphoma Responsive to ProMACE-Based Combination Chemotherapy By Dan L. Longo, Patricia L. Duffey, Elaine S. Jaffe, Mark Raffeld,
Immune checkpoint inhibitors in lymphoma. Catherine Hildyard Haematology Senior Registrar Oxford University Hospitals NHS Foundation Trust
Immune checkpoint inhibitors in lymphoma Catherine Hildyard Haematology Senior Registrar Oxford University Hospitals NHS Foundation Trust Aims How immune checkpoint inhibitors work Success of immune checkpoint
Head and Neck: DLBCL
Head and Neck: DLBCL Nikhil G. Thaker Chelsea C. Pinnix Valerie K. Reed Bouthaina S. Dabaja Department of Radiation Oncology MD Anderson Cancer Center Case 60 yo male Presented with right cervical LAD
Prognostic Value of Early Introduction of Second Line in Patients with Diffuse Large B Cell Lymphoma
Med. J. Cairo Univ., Vol. 84, No., December: 443-447, 6 www.medicaljournalofcairouniversity.net Prognostic Value of Early Introduction of Second Line in Patients with Diffuse Large B Cell Lymphoma HAMDY
Practical Application of PET adapted Therapy in Hodgkin Lymphoma
Practical Application of PET adapted Therapy in Hodgkin Lymphoma Matthew Matasar, MD Lymphoma and Adult BMT Services Director, Lymphoma Survivorship Clinic Memorial Sloan Kettering Cancer Center New York,
Change Summary - Form 2018 (R3) 1 of 12
Summary - Form 2018 (R3) 1 of 12 Form Question Number (r3) Type Description New Text Previous Text Today's date was removed 2018 N/A Today's Date Removed from Key Fields 2018 N/A HCT Type 2018 N/A Product
CD4+/CD56+ Hematodermic Neoplasm Presenting in the Skin: A Tunisian Case Report and Current Review of the Literature
Open Journal of Blood Diseases, 2012, 2, 95-99 http://dx.doi.org/10.4236/ojbd.2012.24018 Published Online December 2012 (http://www.scirp.org/journal/ojbd) 95 CD4+/CD56+ Hematodermic Neoplasm Presenting
CNS Lymphoma. Las Vegas-- March 10-12, 2016
CNS Lymphoma Las Vegas-- March 10-12, 2016 Frequency 3% of primary cerebral tumors 1% of NHLs Recent developments and controversies in PCNSL Hottinger et al Current Opinion in Oncology Vol 27 No. 6 November
PET-adapted therapies in the management of younger patients (age 60) with classical Hodgkin lymphoma
PET-adapted therapies in the management of younger patients (age 60) with classical Hodgkin lymphoma Ryan Lynch MD Assistant Professor, University of Washington Assistant Member, Fred Hutchinson Cancer
High Grade Lymphoma. Trial name & Treatment Key entry criteria Open Sites. Relapsed/Refractory
DISEASE or High Grade Lymphoma DLBCL INCA = Inotuzumab Ozogamicin (INO) + Rituximab + CVP v Gemcitabine + Rituximab + CVP following a steroid pre-phase of pred 60mg x 7 days Second Line Trial name & Treatment
Peripheral T-Cell Lymphoma. Pro auto. Peter Reimer. Klinik für Hämatologie / intern. Onkologie und Stammzelltransplantation
Peripheral T-Cell Lymphoma Pro auto Peter Reimer Klinik für Hämatologie / intern. Onkologie und Stammzelltransplantation Kliniken Essen Süd, Evang. Krankenhaus Essen-Werden ggmbh COSTEM, Berlin 09.09.2011
Dr. Nicolas Ketterer CHUV, Lausanne SAMO, May 2009
Treatment of DLBCL Dr. Nicolas Ketterer CHUV, Lausanne SAMO, May 2009 Non-hodgkin lymphomas DLBCL Most common NHL subtype throughout the world many other types of lymphoma with striking geographic variations
Integrating FDG PET data for lymphoma management. Michel Meignan, France
Integrating FDG PET data for lymphoma management Michel Meignan, France Combining metabolic data from baseline, interim or post treatment PET PET Data can be combined: 1. Together 2. With baseline clinical
Bendamustine for Hodgkin lymphoma. Alison Moskowitz, MD Assistant Attending Memorial Sloan Kettering, Lymphoma Service
Bendamustine for Hodgkin lymphoma Alison Moskowitz, MD Assistant Attending Memorial Sloan Kettering, Lymphoma Service Bendamustine in Hodgkin lymphoma Bifunctional molecule Nitrogen mustard component (meclorethamine)
THE EORTC-GELA TREATMENT STRATEGY IN CLINICAL STAGES I-II HL Results of the H9-F and H9-U trials (#20982)
EORTC Lymphoma Group THE EORTC-GELA TREATMENT STRATEGY IN CLINICAL STAGES I-II HL Results of the H9-F and H9-U trials (#20982) J. Thomas, C. Fermé, E.M. Noordijk, H. Eghbali and M. Henry-Amar 7th International
Clinical analysis of primary systemic anaplastic large cell lymphoma
[Chinese Journal of Cancer 28:1, 49-53; January 2009]; Clinical 2009 analysis Sun Yat-Sen of primary University systemic Cancer anaplastic Centerlarge cell lymphoma: A report of 57 cases Clinical Research
BLOOD RESEARCH REVIEW ARTICLE THE HISTORY OF KLWP-CISL INTRODUCTION
BLOOD RESEARCH VOLUME 48 ㆍ NUMBER 3 September 2013 REVIEW ARTICLE Review of the clinical research conducted by the Consortium for Improving Survival of Lymphoma of the Korean Society of Hematology Lymphoma
Interim PET in Diffuse Large B Cell Lymphoma.The GEL/TAMO experience
Interim PET in Diffuse Large B Cell Lymphoma.The GEL/TAMO experience MD. Caballero, Hospital Universitario, Salamanca, Spain. Chair of The GEL/TAMO Group Menton,9 april 2010 Disclosures for Dolores Caballero
What is the best approach to the initial therapy of PTCL? standards of treatment? Should all
What is the best approach to the initial therapy of PTCL? standards of treatment? hould all Jia Ruan, M.D., Ph.D. Center for Lymphoma and Myeloma Weill Cornell Medical College New York Presbyterian Hospital
Post-ESMO Berne
Post-ESMO Berne 23.10.2015 Lymphoma Update Panagiotis Samaras Department of Oncology Hemato-Oncology Center University Hospital Zurich Diffuse Large B-Cell Lymphoma (DLBCL) PCNSL Hodgkin s Lymphoma Mantle
Induction Therapy & Stem Cell Transplantation for Myeloma
Induction Therapy & Stem Cell Transplantation for Myeloma William Bensinger, MD Professor of Medicine, Division of Oncology University of Washington School of Medicine Director, Autologous Stem Cell Transplant
HODGKIN LYMPHOMA Updated February 2016 by Dr. Manna (PGY 5 Hematology Resident, University of Calgary)
HODGKIN LYMPHOMA Updated February 2016 by Dr. Manna (PGY 5 Hematology Resident, University of Calgary) Reviewed by Dr. Michelle Geddes (Staff Hematologist, University of Calgary) and Dr. Matt Cheung (Staff
Extranodal natural killer T-cell lymphoma, nasal type, presenting as periorbital cellulitis: A case report
CASE REPORT Miller et al. 1 PEER REVIEWED OPEN ACCESS Extranodal natural killer T-cell lymphoma, nasal type, presenting as periorbital cellulitis: A case report Katherine Miller, Amir Kamran, Anna Koget
IAN CROCKER = TIM HOWARD
Winship Cancer Institute of Emory University Radiation as Consolidation in the Treatment of Newly Diagnosed CNS Lymphoma versus After Failure of Chemotherapy Pro: Upfront Radiation Ian Crocker MD, FACR,
Role of prophylactic radiotherapy in Chinese patients with primary testicular diffuse large B-cell lymphoma: a single retrospective study
JBUON 2019; 24(2): 754-762 ISSN: 1107-0625, online ISSN: 2241-6293 www.jbuon.com E-mail: editorial_office@jbuon.com ORIGINAL ARTICLE Role of prophylactic radiotherapy in Chinese patients with primary testicular
Infused autograft lymphocyte-to-monocyte ratio and survival in T-cell lymphoma postautologous peripheral blood hematopoietic stem cell transplantation
Porrata et al. Journal of Hematology & Oncology (2015) 8:80 DOI 10.1186/s13045-015-0178-5 JOURNAL OF HEMATOLOGY & ONCOLOGY RESEARCH ARTICLE Open Access Infused autograft lymphocyte-to-monocyte ratio and
The case against maintenance rituximab in Follicular lymphoma. Jonathan W. Friedberg M.D., M.M.Sc.
The case against maintenance rituximab in Follicular lymphoma Jonathan W. Friedberg M.D., M.M.Sc. Follicular lymphoma: What are goals of treatment? Change natural history of disease: Decrease transformation
CHOP CHEMOTHERAPY OF INTERMEDIATE AND HIGH-GRADE NON-HODGKIN S LYMPHOMA
Aria Oncologicu Vol., No. 8, pp. 95-99, 1994 CHOP CHEMOTHERAPY OF INTERMEDIATE AND HIGH-GRADE NON-HODGKIN S LYMPHOMA MARTA LLANOS, JOSEP TABERNERO, JOAN BRUNET, MARGARITAMENEDO, CINTA PALLARES, LUIS DE
What is the best second-line approach to induce remission prior to stem cell transplant? Single agent brentuximab vedotin
What is the best second-line approach to induce remission prior to stem cell transplant? Single agent brentuximab vedotin Alison Moskowitz, MD Assistant Attending, Lymphoma Service Memorial Sloan Kettering
children and young people:
Hodgkin lymphoma in children and young people: State of the art Professor W. Hamish Wallace RHSC 2016 Childhood Cancer 1971-2010 One-, Five- and Ten-Year Actuarial Survival (%), Children (Aged 0-14),
LYMPHOMA Joginder Singh, MD Medical Oncologist, Mercy Cancer Center
LYMPHOMA Joginder Singh, MD Medical Oncologist, Mercy Cancer Center Lymphoma is cancer of the lymphatic system. The lymphatic system is made up of organs all over the body that make up and store cells
DERBY-BURTON LOCAL CANCER NETWORK FILENAME R-IVE.DOC CONTROLLED DOC NO: HCCPG B53 CSIS Regimen Name: R-IVE. R-IVE Regimen
R-IVE Regimen Available for Routine Use in Burton in-patient Derby in-patient Burton day-case Derby day-case Burton community Derby community Burton out-patient Derby out-patient Indication Relapsed/ refractory
Does BV as part of salvage impact outcome?
Does BV as part of salvage impact outcome? Craig Moskowitz, MD Steven A. Greenberg Chair in Lymphoma Research Member, Memorial Sloan Kettering Cancer Center Professor of Medicine, Weill Medical College
Professor Mark Bower
BHIVA AUTUMN CONFERENCE 2012 Including CHIVA Parallel Sessions Professor Mark Bower Chelsea and Westminster Hospital, London COMPETING INTEREST OF FINANCIAL VALUE > 1,000: Speaker Name Statement Mark Bower
A prospective phase II study of L-asparaginase- CHOP plus radiation in newly diagnosed extranodal NK/T-cell lymphoma, nasal type
Lin et al. Journal of Hematology & Oncology 2013, 6:44 JOURNAL OF HEMATOLOGY & ONCOLOGY RAPID COMMUNICATION Open Access A prospective phase II study of L-asparaginase- CHOP plus radiation in newly diagnosed
Zebras in Dermatopathology
Gonzalo De Toro, MD Puerto Montt - Chile Disclosure of Relevant Financial Relationships. Dr. Gonzalo de Toro declares he has no conflict(s) of interest to disclose. CASE 1 Zebras in Dermatopathology. Relatively